Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kineret is a prescription interleukin-1 receptor antagonist containing anakinra. It is indicated for moderately to severely active rheumatoid arthritis in adults who have failed one or more disease-modifying antirheumatic drugs, neonatal-onset multisystem inflammatory disease, and deficiency of interleukin-1 receptor antagonist.
read more about kineret ...Anakinra blocks the biologic activity of interleukin-1 alpha and interleukin-1 beta by competitively inhibiting their binding to the interleukin-1 type I receptor. This reduces inflammatory signaling involved in rheumatoid arthritis, neonatal-onset multisystem inflammatory disease, and deficiency of interleukin-1 receptor antagonist.
Kineret is used in adults with qualifying rheumatoid arthritis and in patients with neonatal-onset multisystem inflammatory disease or deficiency of interleukin-1 receptor antagonist. Treatment is not started in patients with active infections. Use with tumor necrosis factor blocking medicines is not recommended.
Rheumatoid arthritis uses 100 mg by subcutaneous injection once daily. Neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist start at 1 mg to 2 mg per kg daily and can increase to a maximum of 8 mg per kg daily. Severe kidney impairment can require administration every other day.
Serious concerns include infections, anaphylaxis, angioedema, DRESS, neutropenia, and injection-site amyloid deposits. Neutrophil counts are checked before treatment, monthly for the first three months, and then every three months for up to one year. Live vaccines are not given during treatment.
Current labeling includes rheumatoid arthritis, neonatal-onset multisystem inflammatory disease, and deficiency of interleukin-1 receptor antagonist.
The recommended dose is 100 mg by subcutaneous injection once daily.
The recommended starting dose is 1 mg to 2 mg per kg daily.
Current labeling does not recommend combining Kineret with tumor necrosis factor blocking medicines due to increased serious infection risk.
Anakinra. MedlinePlus. https://medlineplus.gov/druginfo/meds/a602001.html. Date Accessed October 8, 2026.
Anakinra. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Anakinra. Date Accessed October 8, 2026.
DailyMed - KINERET (anakinra) injection, solution. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d9d74915-6606-4570-9c52-c4001d3177de&type=display. Date Accessed October 8, 2026.
KINERET (anakinra) Prescribing Information. Sobi. https://www.kineretrx.com/pdf/Full-Prescribing-Information-English.pdf. Date Accessed October 8, 2026.
Search Orphan Drug Designations and Approvals - Kineret. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=745420. Date Accessed October 8, 2026.